Lower serum endogenous secretory receptor for advanced glycation end product level as a risk factor of metabolic syndrome among japanese adult men: A 2-Year longitudinal study

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 2, 2014, Pages 587-593

  Momma, Haruki ^a   Niu, Kaijun ^c   Kobayashi, Yoritoshi ^b   Huang, Cong ^b   Chujo, Masahiko ^b   Otomo, Atsushi ^b   Tadaura, Hiroko ^d   Miyata, Toshio ^b   Nagatomi, Ryoichi ^a  

^a TOHOKU UNIVERSITY   (Japan)

^b TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c TIANJIN MEDICAL UNIVERSITY   (China)

^d MIYAGI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGE DISTRIBUTION; AGED; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; CALORIC INTAKE; CROSS-SECTIONAL STUDY; DEPRESSION; DIASTOLIC BLOOD PRESSURE; EDUCATIONAL STATUS; ELEVATED BLOOD PRESSURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; INCIDENCE; JAPANESE; LIFESTYLE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OBESITY; OCCUPATION; PHYSICAL ACTIVITY; PREDICTION; PREVALENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; RISK ASSESSMENT; RISK FACTOR; SLEEP TIME; SMOKING; SYSTOLIC BLOOD PRESSURE; TREND STUDY; VERY ELDERLY; WAIST CIRCUMFERENCE;

ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; HUMANS; INCIDENCE; JAPAN; LONGITUDINAL STUDIES; MALE; METABOLIC SYNDROME X; MIDDLE AGED; RECEPTORS, IMMUNOLOGIC; RISK FACTORS;

EID: 84896729099     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-2936     Document Type: Article

References (42)

1. Yan SF, Ramasamy R, Schmidt AM. TheRAGEaxis: a fundamental mechanism signaling danger to the vulnerable vasculature. Circ Res. 2010;106:842-853.
2. Kalea AZ, Schmidt AM, Hudson BI. RAGE: a novel biological and genetic marker for vascular disease. Clin Sci (Lond). 2009;116:621-637.
3. Schmidt AM, Vianna M, Gerlach M, et al. Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J Biol Chem. 1992;267:14987-14997.
4. Bucciarelli LG, Wendt T, Qu W, et al. RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation. 2002;106:2827-2835.
5. Park L, Raman KG, Lee KJ, et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med. 1998;4:1025-1031.
6. Sebekova K, Krivosikova Z, Gajdos M. Total plasma nepsilon- (carboxymethyl) lysine and sRAGE levels are inversely associated with a number of metabolic syndrome risk factors in non-diabetic youngto- middle-aged medication-free subjects. Clin Chem Lab Med. 2013:1-11.
7. Norata GD, Garlaschelli K, Grigore L, et al. Circulating soluble receptor for advanced glycation end products is inversely associated with body mass index and waist/hip ratio in the general population. Nutr Metab Cardiovasc Dis. 2009;19:129-134.
8. Yamagishi S, Adachi H, Nakamura K, et al. Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects. Metabolism. 2006;55:1227-1231.
9. Selvin E, Halushka M,Rawlings A, et al.sRAGEand risk of diabetes, cardiovascular disease and death. Diabetes. 2013;62(6):2116-2121.
10. Colhoun HM, Betteridge DJ, Durrington P, et al. Total soluble and endogenous secretory receptor for advanced glycation end products as predictive biomarkers of coronary heart disease risk in patients with type 2 diabetes: an analysis from the CARDS trial. Diabetes. 2011;60:2379-2385.
11. Koyama H, Shoji T, Fukumoto S, et al. Low circulating endogenous secretory receptor for AGEs predicts cardiovascular mortality in patients with end-stage renal disease. Arterioscler Thromb Vasc Biol. 2007;27:147-153.
12. Fujisawa K, Katakami N, Kaneto H, et al. Circulating solubleRAGE as a predictive biomarker of cardiovascular event risk in patients with type 2 diabetes. Atherosclerosis. 2013;227(2):425-428.
13. Nin JW, Jorsal A, Ferreira I, et al. Higher plasma soluble receptor for advanced glycation end products (sRAGE) levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study. Diabetes. 2010;59:2027-2032.
14. Semba RD, Ferrucci L, Sun K, et al. Advanced glycation end products and their circulating receptors predict cardiovascular disease mortality in older community-dwelling women. Aging Clin Exp Res. 2009;21:182-190.
15. Thomas MC, Soderlund J, Lehto M, et al. Soluble receptor for AGE (RAGE) is a novel independent predictor of all-cause and cardiovascular mortality in type 1 diabetes. Diabetologia. 2011;54:2669-2677.
16. Peng WH, Lu L, Hu J, et al. Decreased serum esRAGE level is associated with angiographically determined coronary plaque progression in diabetic patients. Clin Biochem. 2009;42:1252-1259.
17. Momma H, Niu K, Kobayashi Y, et al. Skin advanced glycation end-product accumulation is negatively associated with calcaneal osteo-sono assessment index among non-diabetic adult Japanese men. Osteoporos Int. 2012;23:1673-1681.
18. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499-511.
19. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640-1645.
20. Wittwer C, Lehner J, Fersching D, Siegele B, Stoetzer OJ, Holdenrieder S. Methodological and preanalytical evaluation of a RAGE immunoassay. Anticancer Res. 2012;32:2075-2078.
21. Sakurai S, Yamamoto Y, Tamei H, et al. Development of an ELISA for esRAGE and its application to type 1 diabetic patients. Diabetes Res Clin Pract. 2006;73:158-165.
22. Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53: 982-992.
23. Craig CL, Marshall AL, Sjostrom M, et al. International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc. 2003;35:1381-1395.
24. Ishikawa-Takata K, Tabata I. Exercise and Physical Activity Reference for Health Promotion 2006 (EPAR2006). J Epidemiol. 2007; 17:177.
25. Kobayashi S, Murakami K, Sasaki S, et al. Comparison of relative validity of food group intakes estimated by comprehensive and brieftype self-administered diet history questionnaires against 16 d dietary records in Japanese adults. Public Health Nutr. 2011;14: 1200-1211.
26. Fukuda K, Kobayashi S. A study on a self-rating depression scale (in Japanese) (author's translation). Seishin Shinkeigaku Zasshi. 1973; 75:673-679.
27. Fountoulakis KN, lacovides A, Samolis S, et al. Reliability, validity and psychometric properties of the Greek translation of the Zung Depression Rating Scale. BMC Psychiatry. 2001;1:6.
28. Kalousova M, Hodkova M, Kazderova M, et al. Soluble receptor for advanced glycation end products in patients with decreased renal function. Am J Kidney Dis. 2006;47:406-411.
29. Santilli F, Bucciarelli L, Noto D, et al. Decreased plasma soluble RAGE in patients with hypercholesterolemia: effects of statins. Free Radic Biol Med. 2007;43:1255-1262.
30. Vazzana N, Santilli F, Cuccurullo C, Davi G. Soluble forms ofRAGE in internal medicine. Intern Emerg Med. 2009;4:389-401.
31. Yang SJ, Kim S, Hwang SY, et al. Association between sRAGE, esRAGE levels and vascular inflammation: analysis with (18)F-fluorodeoxyglucose positron emission tomography. Atherosclerosis. 2012;220:402-406.
32. Yamagishi S, Imaizumi T. Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) may reflect tissue RAGEexpression in diabetes. Arterioscler Thromb Vasc Biol. 2007; 27:e32; author reply e33-34.
33. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/ National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735-2752.
34. Fukami A, Adachi H, Yamagishi S, et al. Factors associated with serum high mobility group box 1 (HMGB1) levels in a general population. Metabolism. 2009;58:1688-1693.
35. Bierhaus A, Nawroth PP. Multiple levels of regulation determine the role of the receptor for AGE (RAGE) as common soil in inflammation, immune responses and diabetes mellitus and its complications. Diabetologia. 2009;52:2251-2263.
36. Kankova K, Marova I, Zahejsky J, et al. Polymorphisms 1704G/T and 2184A/G in the RAGE gene are associated with antioxidant status. Metabolism. 2001;50:1152-1160.
37. Niu W, Qi Y, Wu Z, Liu Y, Zhu D, Jin W. A meta-analysis of receptor for advanced glycation end products gene: four well-evaluated polymorphisms with diabetes mellitus. Mol Cell Endocrinol. 2012;358:9-17.
38. Gaens KH, Ferreira I, van der Kallen CJ, et al. Association of polymorphism in the receptor for advanced glycation end products (RAGE) gene with circulating RAGE levels. J Clin Endocrinol Metab. 2009;94:5174-5180.
39. Yoon SJ, Park S, Shim CY, et al. Association of RAGE gene polymorphisms with coronary artery disease in the Korean population. Coron Artery Dis. 2007;18:1-8.
40. Sullivan CM, Futers TS, Barrett JH, Hudson BI, Freeman MS, Grant PJ. RAGE polymorphisms and the heritability of insulin resistance: the Leeds family study. Diab Vasc Dis Res. 2005;2:42-44.
41. Biswas SK, Mudi SR, Mollah FH, Bierhaus A, Arslan MI. Serum soluble receptor for advanced glycation end products (sRAGE) is independently associated with cigarette smoking in non-diabetic healthy subjects. Diab Vasc Dis Res. 2013;10:380-382.
42. Reynolds PR, Kasteler SD, Cosio MG, Sturrock A, Huecksteadt T, Hoidal JR. RAGE: developmental expression and positive feedback regulation by Egr-1 during cigarette smoke exposure in pulmonary epithelial cells. Am J Physiol Lung Cell Mol Physiol. 2008;294: L1094-L1101.